Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Oriol Arqués
Observed names:
Arques Casamitjana, Oriol,
Arqués, Oriol,
O. Arqués,
Oriol Arqués Casamitjana
Institution:
Vall d'Hebron Institute of Oncology
Observed institutions:
Universitat Autònoma de Barcelona,
Barcelona Biomedical Research Park,
NYU Langone Health,
Institutul National Victor Babes,
Vall d'Hebron Hospital Universitari,
AstraZeneca (Spain),
Vall d'Hebron Institute of Oncology
show all 7
ORCID:
0000-0003-2603-3874
Observed ORCID:
0000-0003-2603-3874
OpenAlex ID:
A5028607008
β-catenin confers resistance to PI3K and AKT inhibitors and subverts FOXO3a to promote metastasis in colon cancer
2012
·
Stephan P Tenbaum
, Paloma Ordóñez-Morán
, et al.
·
Nature Medicine
·
399
MYC targeting by OMO-103 in solid tumors: a phase 1 trial
2024
·
Elena Garralda
, Marie-Eve Beaulieu
, et al.
·
Nature Medicine
·
225
PDF
Tankyrase Inhibition Blocks Wnt/β-Catenin Pathway and Reverts Resistance to PI3K and AKT Inhibitors in the Treatment of Colorectal Cancer
2015
·
Oriol Arqués
, Irene Chicote
, et al.
·
Clinical Cancer Research
·
184
TET2 controls chemoresistant slow-cycling cancer cell survival and tumor recurrence
2018
·
Isabel Puig
, Stephan P. Tenbaum
, et al.
·
Journal of Clinical Investigation
·
118
PDF
A Personalized Preclinical Model to Evaluate the Metastatic Potential of Patient-Derived Colon Cancer Initiating Cells
2013
·
Isabel Puig
, Irene Chicote
, et al.
·
Clinical Cancer Research
·
90
Coordinated Action of CK1 Isoforms in Canonical Wnt Signaling
2011
·
Beatriz del Valle-Pérez
, Oriol Arqués
, et al.
·
Molecular and Cellular Biology
·
87
DualMET andERBB inhibition overcomes intratumor plasticity in osimertinib-resistant-advanced non-small-cell lung cancer (NSCLC)
2017
·
A. Martinez-Marti
, E. Felip
, et al.
·
Annals of Oncology
·
78
PDF
Standardized Relative Quantification of Immunofluorescence Tissue Staining
2012
·
Stephan Tenbaum
, Oriol Arqués
, et al.
·
Protocol Exchange
·
58
PDF
687 Beta-catenin Confers Resistance to PI3K and AKT Inhibitors and Subverts FOXO3a to Promote Metastasis in Colon Cancer
2012
·
S.P. Tenbaum
, P. Ordóñez-Morán
, et al.
·
European Journal of Cancer
·
53
Solid pseudopapillary neoplasms of the pancreas are dependent on the Wnt pathway
2019
·
Pier Selenica
, Nitya Raj
, et al.
·
Molecular Oncology
·
47
PDF
Epigenetic EGFR Gene Repression Confers Sensitivity to Therapeutic BRAFV600E Blockade in Colon Neuroendocrine Carcinomas
2019
·
Jaume Capdevila
, Oriol Arqués
, et al.
·
Clinical Cancer Research
·
41
PDF
Widespread Repression of Gene Expression in Cancer by a Wnt/β-Catenin/MAPK Pathway
2020
·
Nathan Harmston
, Jun Yi Stanley Lim
, et al.
·
Cancer Research
·
33
PDF
Precision Oncology and Systemic Targeted Therapy in Pseudomyxoma Peritonei
2024
·
Jordi Martínez-Quintanilla
, Débora Cabot
, et al.
·
Clinical Cancer Research
·
21
DPPA3-HIF1α axis controls colorectal cancer chemoresistance by imposing a slow cell-cycle phenotype
2023
·
Estefania Cuesta-Borràs
, Cándida Salvans
, et al.
·
Cell Reports
·
11
PDF
Quantitative Procedure to Analyze Nuclear β-Catenin Using Immunofluorescence Tissue Staining
2014
·
Oriol Arqués
, Oriol Arqués
, et al.
·
Protocol Exchange
·
4
PDF
Data from Precision Oncology and Systemic Targeted Therapy in Pseudomyxoma Peritonei
2024
·
Jordi Martínez-Quintanilla
, Débora Cabot
, et al.
·
1
Figure 4 from Precision Oncology and Systemic Targeted Therapy in Pseudomyxoma Peritonei
2024
·
Jordi Martínez-Quintanilla
, Débora Cabot
, et al.
·
1
Author Correction: β-catenin confers resistance to PI3K and AKT inhibitors and subverts FOXO3a to promote metastasis in colon cancer
2026
·
Stephan P. Tenbaum
, Paloma Ordóñez-Morán
, et al.
·
Nature Medicine
PDF
Acquired resistance to BRAF inhibitory treatments requires tumor tissue remodeling and reveals targetable vulnerabilities in colorectal cancer
2025
·
Hector Palmer
, Lorena Ramírez
, et al.
·
Research Square
47P Correlation of clinical, genetic and transcriptomic traits with PD-L1 positivity in TNBC patients
2024
·
A. Semertzidou
, S. Hassanieh
, et al.
·
Immuno-Oncology Technology
PDF
132 (PB120): Pharmacokinetic and pharmacodynamic analyses of OMO-103 in preclinical and patient tissues
2024
·
S. Martínez Martín
, S. Casacuberta-Serra
, et al.
·
European Journal of Cancer
114 (PB102): First-in-class TET2 activator as a new therapeutic strategy to fight cancer
2024
·
D. Aguilar
, I. Puig
, et al.
·
European Journal of Cancer
Supplementary Table 2 from Precision Oncology and Systemic Targeted Therapy in Pseudomyxoma Peritonei
2024
·
Jordi Martínez-Quintanilla
, Débora Cabot
, et al.
Supplementary Figure 6 from Precision Oncology and Systemic Targeted Therapy in Pseudomyxoma Peritonei
2024
·
Jordi Martínez-Quintanilla
, Débora Cabot
, et al.
Supplementary Table 3 from Precision Oncology and Systemic Targeted Therapy in Pseudomyxoma Peritonei
2024
·
Jordi Martínez-Quintanilla
, Débora Cabot
, et al.
Show more works
View as search
Works count:
96
Citation count:
1,455
H-index:
13
I10-index:
14
Year
Topic
Type